Guocan Wang, M.D., Ph.D.
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Associate Professor, Genitourinary Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
Associate Professor, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Regular Member, Department of Cancer Biology/Immunology, MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX
Education & Training
Degree-Granting Education
| 2011 | Sloan-Kettering Institute, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, New York, US, Cancer Biology & Genetics, Ph.D |
| 2004 | University of Southern Mississippi, Hattiesburg, Mississippi, US, Biochemistry, M.S |
| 2001 | Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, US, MD |
Postgraduate Training
| 2011-2016 | Postdoctoral Fellow, Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2011-2011 | Postdoctoral Fellow, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts |
Licenses & Certifications
| 2023 | Controlled Substance - DEA |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Genitourinary Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2024
Assistant Professor, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2024
Extramural Institutional Committee Activities
Committee member, Odyssey Fellowship Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Institutional Biosafety Committee (IBC), The University of Texas MD Anderson Cancer Center, 2017 - Present
Honors & Awards
| 2020 - 2022 | UTMDACC Prostate Cancer SPORE DRP Award, The University of Texas MD Anderson Cancer Center |
| 2018 | MD Anderson Cancer Center Prostate Cancer SPORE Developmental Research Program Award, MD Anderson Cancer Center |
| 2017 | Rising STARS Award, Science and Technology Acquisition and Retention Program, The University of Texas System |
| 2016 - 2018 | UTMDACC Prostate Cancer SPORE CEP Award, The University of Texas MD Anderson Cancer Center |
| 2016 | Ben F. Love Endowed Fellowship in Innovative Cancer Therapies, The University of Texas MD Anderson Cancer Center |
| 2016 | K99/R00 Pathway to Independence Award, NIH |
| 2015 | AMGEN Award for Basic Science Research, The University of Texas MD Anderson Cancer Center |
| 2013 | Post-doctoral Fellowship, Department of Defense |
| 2009 | Pre-doctoral Fellowship, Department of Defense |
| 2006 | Vincent du Vigneaud Awards of Excellence, Weill Graduate School of Medical Sciences |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2015. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Conference. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Houston, TX, US.
Regional Presentations
- 2007. The role of LRF in hepatocellular carcinogenesis and metabolism. Conference. The role of LRF in hepatocellular carcinogenesis and metabolism. New York, NY, US.
- 2006. Phosphorylation-dependent regulation of SCF complex formation and Skp2 function by Akt/PKB. Conference. Phosphorylation-dependent regulation of SCF complex formation and Skp2 function by Akt/PKB. New York, NY, US.
- 2003. In vitro selection of a minimum RNA ligase ribozyme. Conference. In vitro selection of a minimum RNA ligase ribozyme. Gulfport, MS, US.
National Presentations
- 2024. ACOD1 is a key regulator of immunosuppressive MDSCs, prostate cancer progression, and resistance to immunotherapy. Conference. ACOD1 is a key regulator of immunosuppressive MDSCs, prostate cancer progression, and resistance to immunotherapy. San Diego, CA, US.
- 2023. KDMA4 promotes NEPC progression through regulation of MYC expression. Conference. KDMA4 promotes NEPC progression through regulation of MYC expression. Orlando, FL, US.
- 2017. Targeting Yap-dependent MDSC infiltration impairs tumor progression. Conference. Targeting Yap-dependent MDSC infiltration impairs tumor progression. Houston, TX, US.
- 2011. LRF: a novel tumor suppressor gene in prostate cancer. Conference. LRF: a novel tumor suppressor gene in prostate cancer. Orlando, FL, US.
- 2009. The role of LRF as a novel tumor suppressor in prostate cancer. Conference. The role of LRF as a novel tumor suppressor in prostate cancer. Taos, NM, US.
Formal Peers
- 2023. Histone Lysine Demethylase KDMA4 as a Driver in Neuroendocrine Prostate Cancer. Invited, US.
- 2021. Transcriptional and epigenetic dysregulations in prostate cancer progression. Invited, TX, US.
Grant & Contract Support
| Date: | 2027 - 2032 |
| Title: | Stromal ECM remodeling in diffuse gastric cancer |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | R01 CA311075-01A1 |
| Date: | 2027 - 2032 |
| Title: | BMP4-osteomimicry axis in castration resistance and osteogenic bone metastasis of prostate cancer |
| Funding Source: | NIH |
| Role: | PI |
| ID: | 1R01CA322295-01 |
| Date: | 2026 - 2031 |
| Title: | The Epigenetic Modifier JARID1D and its Corepressors in Regulation of Prostate Cancer Metastasis |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP00020586_Res1 |
| Date: | 2026 - 2031 |
| Title: | Prostate Cancer-Induced Bone Formation Regulates Immune Microenvironment in Prostate Cancer Bone Metastasis |
| Funding Source: | NIH |
| Role: | PI |
| ID: | FP29189 |
| Date: | 2026 - 2029 |
| Title: | Targeting ACOD1 in PMN-MDSCs as a Novel Approach to Overcome Immunotherapy Resistance in Bone Metastases of Prostate Cancer |
| Funding Source: | CPRIT |
| Role: | PI |
| ID: | RP270081 |
| Date: | 2026 - 2029 |
| Title: | Targeting the Metabolic Checkpoint ACOD1 as a Novel Therapeutic Strategy in Prostate Cancer Bone Metastasis |
| Funding Source: | DOD PCRP-IDA |
| Role: | PI |
| ID: | PC250331 |
| Date: | 2026 - 2028 |
| Title: | Targeting the Androgen Receptor to Enhance Anti-Tumor Neutrophil Infiltration and Overcome Immunotherapy Resistance in Undifferentiated Pleomorphic Sarcoma |
| Funding Source: | DOD-RCRP |
| Role: | PI |
| ID: | RA250861 |
| Date: | 2026 - 2031 |
| Title: | PMN-MDSC in Bone-TME of Prostate Cancer Bone Metastasis |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01 |
| Date: | 2026 - 2028 |
| Title: | Epigenetic–Metabolic Reprogramming as a Therapeutic Target to Overcome Immunotherapy Resistance in NEPC |
| Funding Source: | MD Anderson |
| Role: | PI |
| Date: | 2026 - 2031 |
| Title: | Cancer Cell-Intrinsic And -Extrinsic Function of Dopa Decarboxylase (DDC) In NEPC Progression and Immunotherapy Resistance |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01 CA311378-01 |
| Date: | 2026 - 2030 |
| Title: | Targeting KDM4A as a Novel Therapy for High-Grade Neuroendocrine Tumors and Carcinomas |
| Funding Source: | Neuroendocrine Tumor Research Foundation (NETRF) |
| Role: | PI |
| Date: | 2026 - 2027 |
| Title: | KDM4A-FADS ½ axis in driving metastasis and immunotherapy resistance in NEPC |
| Funding Source: | MD Anderson |
| Role: | PI |
| Date: | 2026 - 2027 |
| Title: | Reprogramming PMN-MDSCs via NRF2–SLC7A11 Inhibition to Enhance Ferroptosis and Immunotherapy Response in Prostate Cancer |
| Funding Source: | OhioHealth and MD Anderson Cancer Center Birdie for Buddies Prostate Research Grant |
| Role: | PI |
| Date: | 2026 - 2026 |
| Title: | Targeting the Myeloid Metabolic Checkpoint ACOD1 to Overcome Immunotherapy Resistance in Prostate Cancer Bone Metastasis |
| Funding Source: | Mike Slive Foundation |
| Role: | PI |
| Date: | 2025 - 2026 |
| Title: | Sarcoma SPORE, DRP Award: Targeting the Androgen Receptor to Enhance Anti-Tumor Neutrophil Infiltration and Overcome Immunotherapy Resistance in Undifferentiated Pleomorphic Sarcoma |
| Funding Source: | NIH/NCI-Developmental Research Program (DRP) |
| Role: | DRP Award Principal Investigator |
| ID: | P50 CA302482 |
| Date: | 2025 - 2028 |
| Title: | Targeting ACOD1 in PMN-MDSCs as a Novel Approach to Overcome Immunotherapy Resistance in Bone Metastases of Prostate Cancer |
| Funding Source: | CPRIT |
| Role: | PI |
| ID: | RP260044 |
| Date: | 2025 - 2026 |
| Title: | The Role of KDM4A-H19 Axis in Neuroendocrine Prostate Cancer Metastasis |
| Funding Source: | MD Anderson |
| Role: | PI |
| ID: | R01 CA307019 Bridge funding |
| Date: | 2025 - 2028 |
| Title: | Targeting PRMT3-IGF2BP1 Axis-Mediated Epitranscriptomic Reprogramming as a Novel Therapeutic Strategy to Overcome Immunotherapy Resistance in ccRCC |
| Funding Source: | Department of Defense |
| Role: | PI |
| ID: | KC240193 |
| Date: | 2025 - 2027 |
| Title: | DLL3-Directed Antibody-Drug Conjugate Targeting KDM4A as a Novel Therapy for Neuroendocrine Neoplasms |
| Funding Source: | John S. Dunn Foundation |
| Role: | PI |
| Date: | 2025 - 2026 |
| Title: | ACOD1 as a Metabolic Checkpoint in Myeloid Cells Promoting Breast Cancer Brain Metastasis and Immunotherapy Resistance |
| Funding Source: | MD Anderson’s Andrew M. McDougall Brain Metastasis Clinic and Research Program |
| Role: | PI |
| Date: | 2025 - 2026 |
| Title: | Targeting the Myeloid Metabolic Checkpoint ACOD1 as a Novel Therapy to Overcome Immunotherapy Resistance in Ovarian Cancer |
| Funding Source: | MD Anderson DRP Ovarian SPORE |
| Role: | PI |
| Date: | 2025 - 2027 |
| Title: | Targeting Dopa Decarboxylase-Mediated Metabolic Reprogramming as a Novel Strategy to Improve the Efficacy of Immunotherapy in Prostate Adenocarcinoma |
| Funding Source: | DOD-PCRP-Exploration-Hypothesis-Development Award |
| Role: | PI |
| ID: | PC240047 |
| Date: | 2025 - 2027 |
| Title: | Administrative Supplement of Cis-Aconitate Decarboxylase (ACOD1) in PMN-MDSC and Prostate Cancer Progression |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01 CA276235-03 |
| Date: | 2025 - 2030 |
| Title: | The Epigenetic Regulator JARID1D in Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA303327-01 |
| Date: | 2025 - 2030 |
| Title: | Prostate Cancer-Induced Bone Formation Regulates Immune Microenvironment in Prostate Cancer Bone Metastasis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | CA278987-01A1 |
| Date: | 2025 - 2026 |
| Title: | H3K36me3/H3K9me3 Demethylases KDM4A and KDM4B as a Novel Therapeutic Strategy in Clear Cell Renal Cell Carcinoma |
| Funding Source: | The Elsa U. Pardee Foundation |
| Role: | PI |
| ID: | n/a |
| Date: | 2025 - 2028 |
| Title: | A Novel Therapeutic Strategy to Treat and Prevent Visceral Metastasis in Neuroendocrine Prostate Cancer |
| Funding Source: | CPRIT |
| Role: | PI |
| ID: | RP250150 |
| Date: | 2025 - 2025 |
| Title: | Targeting Dopa Decarboxylase (DDC)-Dependent Metabolic Reprogramming to Overcome Immunotherapy Resistance in NEPC |
| Funding Source: | The Mike Slive Foundation |
| Role: | PI |
| ID: | 2024-2025 Pilot Research Grant |
| Date: | 2025 - 2026 |
| Title: | The Role of PRMT3 in ccRCC Tumor Progression and Immunotherapy Resistance |
| Funding Source: | Institutional Research Grant (IRG) Program |
| Role: | PI |
| ID: | n/a |
| Date: | 2024 - 2025 |
| Title: | The Chromatin-Dependent and -Independent Functions of KDM4A in Small Cell Lung Cancer (SCLC) |
| Funding Source: | NIH/Lung SPORE - Career Enhancement Program |
| Role: | PI |
| Date: | 2024 - 2029 |
| Title: | MD Anderson Cancer Center Prostate Cancer SPORE Project 2: Targeting EC-to-OSB Transition to Overcome Immunosuppressive Bone Tumor Microenvironment in Bone-Metastatic Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | P50 CA288272-01 |
| Date: | 2024 - 2029 |
| Title: | KDM4A in the Metastasis of Neuroendocrine Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01 CA275899-01A1 |
| Date: | 2024 - 2027 |
| Title: | Dissection of CAMKK2’s Tumor Cell-Intrinsic and –Extrinsic Roles in Prostate Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP240072 |
| Date: | 2024 - 2027 |
| Title: | JARID1D and its Corepressors in Regulation of Prostate Cancer Metastasis |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP240041 |
| Date: | 2024 - 2027 |
| Title: | A Novel Therapeutic Strategy Targeting Metastasis of Neuroendocrine Prostate Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP240261 |
| Date: | 2023 - 2028 |
| Title: | Endothelial-to-Osteoblast Transition in Prostate Cancer Bone Metastasis |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | R01 CA174798-11 |
| Date: | 2023 - 2025 |
| Title: | The Role of DOPA Decarboxylase (DDC) in regulating Metabolic Reprograming in NEPC and Resistance to Immune Checkpoint Therapy |
| Funding Source: | MDACC IRG Grant |
| Role: | PI |
| Date: | 2023 - 2024 |
| Title: | Priority Project 3: Linking One-Carbon Metabolism to Lineage Promiscuity in Aggressive Variant Prostate Cancers (AVPC) |
| Funding Source: | MD Anderson, Moon Shot Program |
| Role: | Co-Program Leader |
| ID: | Prostate Moon Shot |
| Date: | 2023 - 2024 |
| Title: | Developing Clinically Relevant Genetic Mouse for Upper Track Urothelial Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | KC220053 |
| Date: | 2023 - 2024 |
| Title: | KDM4A in the Metastasis of Neuroendocrine Prostate Cancer |
| Funding Source: | MD Anderson Bridge Funding |
| Role: | PI |
| ID: | RCTS-2023-00062658-Y1 |
| Date: | 2023 - 2026 |
| Title: | A Novel Combination Therapeutic Approach to Revitalizing Immunotherapy for Bone Metastatic Prostate Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP230247 |
| Date: | 2023 - 2027 |
| Title: | Cis-Aconitate Decarboxylase (ACOD1) in PMN-MDSC and Prostate Cancer Progression |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01 CA276235-03 |
| Date: | 2022 - 2023 |
| Title: | Prostate MoonShot Priority Project 2: Targeting Prostate Tumor-Induced Bone Formation to Reserve the Immunosuppressive Bone-TME and Improve the Efficacy of Immune Checkpoint Therapies |
| Funding Source: | MD Anderson, Moon Shot Program |
| Role: | Collaborator |
| ID: | Prostate Moon Shot |
| Date: | 2022 - 2025 |
| Title: | A Novel Therapy Targeting the Immune Suppressive Environment of Bone Metastasis |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-PI |
| Date: | 2022 - 2024 |
| Title: | Targeting Prostate Tumor-induced Bone Formation and the Immunosuppressive Microenvironment to Improve the Efficacy of immune Checkpoint Therapies |
| Funding Source: | PCF |
| Role: | Co-I |
| ID: | 2022CHAL3721 |
| Date: | 2022 - 2027 |
| Title: | Epigenome reprogramming and targeting in aggressive variant prostate cancers |
| Funding Source: | NIH |
| Role: | Co-I |
| Date: | 2022 - 2023 |
| Title: | Delineate the Epigenetic/Transcriptional Programs in Driving Metastasis of Neuroendocrine Prostate Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | CGC-FY22-02 |
| Date: | 2022 - 2025 |
| Title: | Mechanisms and Therapies Focused on Epigenetic Alterations in Therapy-Resistant Prostate Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP220410 |
| Date: | 2022 - 2027 |
| Title: | Histone Modifiers and Enhancer Reprogramming in Prostate Cancer Metastasis |
| Funding Source: | NIH |
| Role: | Co-I |
| Date: | 2022 - 2022 |
| Title: | Targeting Immunometabolism for the Treatment of Lethal Prostate Cancer |
| Funding Source: | Mike Slive Foundation |
| Role: | PI |
| Date: | 2021 - 2023 |
| Title: | The Role of Acod1 in Polymorphonuclear Myeloid-Derived Suppressor Cells and Prostate Cancer Progression |
| Funding Source: | MD Anderson IRG Grant |
| Role: | PI |
| Date: | 2021 - 2024 |
| Title: | PC200420:Targeting Histone Lysine Demethylase KDM4A in Neuroendocrine Prostate Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | W81XWH-21-1-0522 |
| Date: | 2021 - 2026 |
| Title: | The role of KDM4A in the pathogenesis of neuroendocrine prostate cancer |
| Funding Source: | NIH |
| Role: | PI |
| Date: | 2021 - 2024 |
| Title: | Targeting Cell-autonomous and Non-cell-autonomous Functions of CAMKK2 for the Treatment of Lethal Prostate Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | PC200421 |
| Date: | 2021 - 2023 |
| Title: | The role of Acod1-mediated metabolic reprogramming in shaping the immunosuppressive tumor microenvironment |
| Funding Source: | John S Dunn Research Foundation |
| Role: | PI |
| Date: | 2020 - 2023 |
| Title: | Eradicate Aggressive Variant Prostate Cancer by Reprogramming Myeloid-Derived Suppressor Cells to Activate Anti-Tumor Innate Immunity |
| Funding Source: | DOD – PCRP Idea |
| Role: | PI |
| ID: | PC190113 |
| Date: | 2020 - 2022 |
| Title: | Unsalaried Investigate Co-Inhibition for Histone Lysine Demethylase KDM4 and PARP1 as a Novel Synthetic Lethal Approach in Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | P5 CA140388 DRP Award |
| Date: | 2020 - 2025 |
| Title: | Epigenetic Modifiers and Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA255885 |
| Date: | 2020 - 2023 |
| Title: | Prostate cancer tryptophan metabolism alters the immune microenvironment and promotes aggressive variant phenotype |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Co-I |
| ID: | PC190355 / FP#:9129 |
| Date: | 2020 - 2022 |
| Title: | Targeting Histone Lysine Demethylase in Aggressive Variant Prostate Cancer |
| Funding Source: | MD Anderson – Institutional Research Grant |
| Role: | PI |
| ID: | IRG |
| Date: | 2020 - 2022 |
| Title: | Cabozantinib increases efficacy of immune checkpoint blockade by comprehensively remodeling the tumor associated microenvironment in prostate cancer bone metastasis |
| Funding Source: | Prostate Cancer Foundation |
| Role: | Co-Primary Investigator |
| ID: | 2020CHAL3247 |
| Date: | 2020 - 2021 |
| Title: | Prostate Cancer Moon Shot PP4: Cabozantinib increases efficacy of immune checkpoint blockade by comprehensively remodeling tumor associate microenvironment in prostate cancer bone metastasis (Lin/Logothetis) |
| Funding Source: | MD Anderson Moon Shot |
| Role: | Co-I |
| Date: | 2020 - 2022 |
| Title: | Targeting MDSCs as a Novel Strategy in Chemoprevention of Aggressive Variant Prostate Cancer |
| Funding Source: | Duncan Family Institute |
| Role: | PI |
| Date: | 2020 - 2022 |
| Title: | Eradicate aggressive variant prostate cancer by targeting histone demethylase KDM4 and myeloid-derived suppressor cells |
| Funding Source: | Andrew Sabin Family Foundation |
| Role: | PI |
| ID: | Sabin Fellowship |
| Date: | 2019 - 2021 |
| Title: | Elucidate the epigenetic landscape in the immunosuppressive myeloid-derived suppressor cells (MDSCs) in prostate cancers that are resistant to immunotherapy |
| Funding Source: | John S. Dunn Collaborative Research Award Program |
| Role: | PI |
| Date: | 2018 - 2019 |
| Title: | Targeting myeloid cells to overcome resistance to immune checkpoint therapies in prostate cancer |
| Funding Source: | NIH/NCI |
| Role: | PI, DRP Award |
| ID: | P50 CA140388-08 |
| Date: | 2018 - 2019 |
| Title: | Targeting the immunosuppressive compartment of the prostate cancer bone metastatic microenvironment to improve clinical outcomes |
| Funding Source: | SPORE |
| Role: | Investigator |
| Date: | 2018 - 2021 |
| Title: | MDSC-Tumor Crosstalk in Prostate Cancer Progression and Castration Resistance |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 4-R00 CA194289 |
| Date: | 2018 - 2020 |
| Title: | Targeting the Tumor Microenvironment in Aggressive Variant Prostate Cancer |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| ID: | Institutional Research Grant |
| Date: | 2018 - 2021 |
| Title: | Initiative for Genetically Engineered Mouse Models (GEMM) in Genitourinary Cancers |
| Funding Source: | MD Anderson Prostate Cancer Res Program |
| Role: | PI |
| ID: | PCRP |
| Date: | 2017 - 2019 |
| Title: | The University of Texas Rising Stars Award |
| Funding Source: | The University of Texas Board of Reagents |
| Role: | PI |
| ID: | UT Rising Stars Award |
| Date: | 2017 - 2018 |
| Title: | Prostate Cancer Moon Shot Flagship 2: Targeting Immune Tumor-Associated Microenvironment in Prostate Cancer |
| Funding Source: | MD Anderson, Moon Shot Program |
| Role: | Investigator |
| ID: | Prostate Moon Shot |
| Date: | 2016 - 2018 |
| Title: | Targeting the Immune Suppressive Tumor Microenvironment in Prostate Cancer Metastasis |
| Funding Source: | UTMDACC Prostate Cancer SPORE Program |
| Role: | PI |
| ID: | UTMDACC Prostate Cancer SPORE CEP Award |
| Date: | 2016 - 2017 |
| Title: | MDSC-tumor crosstalk in prostate cancer progression |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1K99CA194289 |
| Date: | 2013 - 2015 |
| Title: | Functional Genomics to Identify Therapeutic Targets in Cancer Stem Cells Using a Novel Murine CRPC Model |
| Funding Source: | DOD – Postdoctoral Training Award |
| Role: | PI |
| ID: | W81XWH-13-1-0202 |
| Date: | 2013 - 2015 |
| Title: | The role of SMAD4 in prostate cancer initiating cells and castration resistance |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | W81XWH-13-1-0202 |
| Date: | 2009 - 2012 |
| Title: | Study of the Role of a Putative Tumor Suppressor LRF in Prostate Carcinogenesis |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | W81XWH-09-1-0643 |
Selected Publications
Peer-Reviewed Articles
- Mak CSL, Zhu M, Fu J, Liang X, Wang X, Yuan F, Wang F, Hoang AG, Song X, Shepherd P, Liang D, Suh J, Contreras J, Dang T, Yan C, Figueroa B, Mazzocco M, Luo A, Pradhan B, Park J, Bashir M, Zhang M, Metzger E, Schule R, Jain AK, Karasik E, Frigo D, Foster BA, Lee MG, Corn P, Logothetis CJ, Aparicio A, Navone N, Troncoso P, Tan Z, Zhang J, Lin SH, Wang G. KDM4A promotes NEPC progression through regulation of MYC expression. Cancer Letters 638, 2026. e-Pub 2026. PMID: 41319861.
- Corn PG, Yu G, Fan Y, Zhang M, Troncoso P, Surasi DS, Liu S, Ajani JA, Logothetis CJ, Wang G, Panaretakis T, Lin SH. Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment. Prostate Cancer Prostatic Dis, 2025. e-Pub 2025. PMID: 41454189.
- Shi Y, Wu Z, Liu S, Zuo D, Niu Y, Qiu Y, Qiao L, He W, Qiu J, Yuan Y, Wang G, Li B. Targeting PRMT3 impairs methylation and oligomerization of HSP60 to boost anti-tumor immunity by activating cGAS/STING signaling. Nat Commun 15(1):7930, 2024. e-Pub 2024. PMID: 39256398.
- Yu G, Corn PG, Mak CSL, Liang X, Zhang M, Troncoso P, Song JH, Lin SC, Song X, Liu J, Zhang J, Logothetis CJ, Melancon MP, Panaretakis T, Wang G, Lin SH. Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization. Proc Natl Acad Sci U S A 121(33):e2402903121, 2024. e-Pub 2024. PMID: 39102549.
- Shi Y, Niu Y, Yuan Y, Li K, Zhong C, Qiu Z, Li K, Lin Z, Yang Z, Zuo D, Qiu J, He W, Wang C, Liao Y, Wang G, Yuan Y, Li B. PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer. Nat Commun 14(1):1932, 2023. e-Pub 2023. PMID: 37024475.
- Lin SC, Yu G, Lee YC, Song JH, Song X, Zhang J, Panaretakis T, Logothetis CJ, Komatsu Y, Yu-Lee LY, G* W, SH* L. Endothelial-to-osteoblast transition in normal mouse bone development. iScience 26(2):105994, 2023. e-Pub 2023. PMID: 36798441.
- Yang Y, Di Ruscio A, Inoue S, Wang G, Gao S. Editorial: Interplay between epigenetic modifiers and transcription factors in driving cancer progression. Front Oncol 13:1211537, 2023. e-Pub 2023. PMID: 37404748.
- Lee YC, Lin SC, Yu G, Zhu M, Song JH, Rivera K, Pappin DJ, Logothetis CJ, Panaretakis T, Wang G, Yu-Lee LY, Lin SH. Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition. Oncogene 41(6):757-769, 2022. e-Pub 2022. PMID: 34845375.
- Zhu M, Peng R, Liang X, Lan Z, Tang M, Hou P, Song JH, Mak CSL, Park J, Zheng SE, Huang A, Ma X, Chen R, Chang Q, Logothetis CJ, Jain AK, Lin SH, Katayama H, Hanash S, Wang G. P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis. Oncogene 40(41):6049-6056, 2021. e-Pub 2021. PMID: 34471235.
- Chen R, Liang X, Murray MM, Karasik E, Han JJ, Zhu M, Foster BA, Frigo DE, Wang G. A simple quantitative PCR assay to determine TRAMP transgene zygosity. Prostate Cancer Prostatic Dis 24(2):358-361, 2021. e-Pub 2021. PMID: 32895469.
- Yu G, Shen P, Lee YC, Pan J, Song JH, Pan T, Lin SC, Liang X, Wang G, Panaretakis T, Logothetis CJ, Gallick GE, Yu-Lee LY, Lin SH. Multiple pathways coordinating reprogramming of endothelial cells into osteoblasts by BMP4. iScience 24(4):102388, 2021. e-Pub 2021. PMID: 33981975.
- Chakravarti D, Hu B, Mao X, Rashid A, Li J, Li J, Liao WT, Whitley EM, Dey P, Hou P, LaBella KA, Chang A, Wang G, Spring DJ, Deng P, Zhao D, Liang X, Lan Z, Lin Y, Sarkar S, Terranova C, Deribe YL, Blutt SE, Okhuysen P, Zhang J, Vilar E, Nielsen OH, Dupont A, Younes M, Patel KR, Shroyer NF, Rai K, Estes MK, Wang YA, Bertuch AA, DePinho RA. Telomere dysfunction activates YAP1 to drive tissue inflammation. Nat Commun 11(1):4766, 2020. e-Pub 2020. PMID: 32958778.
- Zhao D, Cai L, Lu X, Liang X, Li J, Chen P, Ittmann M, Shang X, Jiang S, Li H, Meng C, Flores I, Song JH, Horner JW, Lan Z, Wu CJ, Li J, Chang Q, Chen KC, Wang G, Deng P, Spring DJ, Wang YA, DePinho RA. Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer. Cancer Discov 10(9):1374-1387, 2020. e-Pub 2020. PMID: 32385075.
- Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. Clin Cancer Res 26(5):990-999, 2020. e-Pub 2020. PMID: 31941830.
- Su W, Han HH, Wang Y, Zhang B, Zhou B, Cheng Y, Rumandla A, Gurrapu S, Chakraborty G, Su J, Yang G, Liang X, Wang G, Rosen N, Scher HI, Ouerfelli O, Giancotti FG. The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. Cancer Cell 36(2):139-155.e10, 2019. e-Pub 2019. PMID: 31327655.
- Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, Li J, Wang G, Lan Z, Li J, Tang M, Jiang S, Ma X, Chen P, Katkhuda R, Korphaisarn K, Chakravarti D, Chang A, Spring DJ, Chang Q, Zhang J, Maru DM, Maeda DY, Zebala JA, Kopetz S, Wang YA, DePinho RA. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. e-Pub 2019. PMID: 30905761.
- Jayaprakash P, Ai M, Liu A, Budhani P, Bartkowiak T, Sheng J, Ager C, Nicholas C, Jaiswal AR, Sun Y, Shah K, Balasubramanyam S, Li N, Wang G, Ning J, Zal A, Zal T, Curran MA. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. J Clin Invest 128(11):5137-5149, 2018. e-Pub 2018. PMID: 30188869.
- Wang H, Yang X, Liu A, Wang G, Bosland MC, Yang CS. δ-Tocopherol inhibits the development of prostate adenocarcinoma in prostate specific Pten-/- mice. Carcinogenesis 39(2):158-169, 2018. e-Pub 2018. PMID: 29121168.
- Bezzi M, Seitzer N, Ishikawa T, Reschke M, Chen M, Wang G, Mitchell C, Ng C, Katon J, Lunardi A, Signoretti S. Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. Nature Medicine 24(2):165, 2018. e-Pub 2018.
- Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Sauvé CG, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGW. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell 32(1):42-56.e6, 2017. e-Pub 2017. PMID: 28697342.
- Zhao D, Lu X, Wang G, Lan Z, Liao W, Li J, Liang X, Chen JR, Shah S, Shang X, Tang M, Deng P, Dey P, Chakravarti D, Chen P, Spring DJ, Navone NM, Troncoso P, Zhang J, Wang YA, DePinho RA. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature 542(7642):484-488, 2017. e-Pub 2017. PMID: 28166537.
- Hu B, Wang Q, Wang YA, Hua S, Sauvé CG, Ong D, Lan ZD, Chang Q, Ho YW, Monasterio MM, Lu X, Zhong Y, Zhang J, Deng P, Tan Z, Wang G, Liao WT, Corley LJ, Yan H, Zhang J, You Y, Liu N, Cai L, Finocchiaro G, Phillips JJ, Berger MS, Spring DJ, Hu J, Sulman EP, Fuller GN, Chin L, Verhaak RG, DePinho RA. Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. Cell 167(5):1281-1295.e18, 2016. e-Pub 2016. PMID: 27863244.
- Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, Fang Z, Zhao K, Konaparthi R, Hua S, Zhang J, Li-Ning-Tapia EM, Kapoor A, Wu CJ, Patel NB, Guo Z, Ramamoorthy V, Tieu TN, Heffernan T, Zhao D, Shang X, Khadka S, Hou P, Hu B, Jin EJ, Yao W, Pan X, Ding Z, Shi Y, Li L, Chang Q, Troncoso P, Logothetis CJ, McArthur MJ, Chin L, Wang YA, DePinho RA. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. Cancer Discov 6(1):80-95, 2016. e-Pub 2016. PMID: 26701088.
- Liu XS, Chandramouly G, Rass E, Guan Y, Wang G, Hobbs RM, Rajendran A, Xie A, Shah JV, Davis AJ, Scully R, Lunardi A, Pandolfi PP. LRF maintains genome integrity by regulating the non-homologous end joining pathway of DNA repair. Nat Commun 6:8325, 2015. e-Pub 2015. PMID: 26446488.
- Guarnerio J, Riccardi L, Taulli R, Maeda T, Wang G, Hobbs RM, Song MS, Sportoletti P, Bernardi R, Bronson RT, Castillo-Martin M, Cordon-Cardo C, Lunardi A, Pandolfi PP. A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells. Cancer Discov 5(4):396-409, 2015. e-Pub 2015. PMID: 25614485.
- Watson IR, Li L, Cabeceiras PK, Mahdavi M, Gutschner T, Genovese G, Wang G, Fang Z, Tepper JM, Stemke-Hale K, Tsai KY, Davies MA, Mills GB, Chin L. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. Cancer Res 74(17):4845-52, 2014. e-Pub 2014. PMID: 25056119.
- Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster KA, Tay Y, Gonzalez-Billalabeitia E, Egia A, Shaffer DR, Carver B, Liu XS, Taulli R, Kuo WP, Nardella C, Signoretti S, Cordon-Cardo C, Gerald WL, Pandolfi PP. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat Genet 45(7):739-46, 2013. e-Pub 2013. PMID: 23727861.
- Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet 45(7):747-55, 2013. e-Pub 2013. PMID: 23727860.
- Ding Z, Wu CJ, Jaskelioff M, Ivanova E, Kost-Alimova M, Protopopov A, Chu GC, Wang G, Lu X, Labrot ES, Hu J, Wang W, Xiao Y, Zhang H, Zhang J, Zhang J, Gan B, Perry SR, Jiang S, Li L, Horner JW, Wang YA, Chin L, DePinho RA. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 148(5):896-907, 2012. e-Pub 2012. PMID: 22341455.
- Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, Cordon-Cardo C, Teruya-Feldstein J, Pandolfi PP. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464(7287):374-9, 2010. e-Pub 2010. PMID: 20237562.
- Maeda T, Ito K, Merghoub T, Poliseno L, Hobbs RM, Wang G, Dong L, Maeda M, Dore LC, Zelent A, Luzzatto L, Teruya-Feldstein J, Weiss MJ, Pandolfi PP. LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis. Dev Cell 17(4):527-40, 2009. e-Pub 2009. PMID: 19853566.
- Lin HK, Wang G, Chen Z, Teruya-Feldstein J, Liu Y, Chan CH, Yang WL, Erdjument-Bromage H, Nakayama KI, Nimer S, Tempst P, Pandolfi PP. Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol 11(4):420-32, 2009. e-Pub 2009. PMID: 19270694.
- Coleman TM, Wang G, Huang F. Superior 5' homogeneity of RNA from ATP-initiated transcription under the T7 phi 2.5 promoter. Nucleic Acids Res 32(1):e14, 2004. e-Pub 2004. PMID: 14744982.
- Huang F, Wang G, Coleman T, Li N. Synthesis of adenosine derivatives as transcription initiators and preparation of 5' fluorescein- and biotin-labeled RNA through one-step in vitro transcription. RNA 9(12):1562-70, 2003. e-Pub 2003. PMID: 14624011.
Invited Articles
- Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and Biology of Prostate Cancer. Genes Dev 32(17-18):1105-1140, 2018. e-Pub 2018. PMID: 30181359.
- Wang G, Gao Y, Li L, Jin G, Cai Z, Chao J, Lin H. K63-linked ubiquitination in kinase activation and cancer. Frontier Oncology, 2012. e-Pub 2012. PMID: 22649774.
- Wang G, Chan CH, Gao Y, Lin HK. Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis. Chin J Cancer 31(4):169-77, 2011. e-Pub 2011. PMID: 22200179.
Review Articles
- Lunardi A, Guarnerio J, Wang G, Maeda T, Pandolfi PP. Role of LRF/Pokemon in lineage fate decisions. Blood 121(15):2845-53, 2013. e-Pub 2013. PMID: 23396304.
Abstracts
- Ling Mak CS, Zhu M, Liang X, Wang F, Hoang AG, Song X, Shepherd P, Liang D, Suh J, Park J, Zhang M, Metzger E, Schule R, Jain AK, Karasik E, Foster BA, Lee MG, Corn P, Logothetis CJ, Aparicio A, Navone N, Troncoso P, Zhang J, Lin S, Wang G. KDM4A promotes NEPC progression through regulation of MYC expression. AACR, 2023. e-Pub 2023.
Book Chapters
- Wang G, Gao Y, Chen L, Wang YJ, Lin HK. Regulation of the Novel Senescence Pathway by SKP2 E3 Ligase. In: Tumor Dormancy and Cellular Quiescence and Senescence, 33-43, 2013.
Patient Reviews
CV information above last modified July 24, 2026